利伐沙班治疗静脉血栓效果如何?
(Rivaroxaban) is a small molecule oral anticoagulant jointly developed by Bayer and Johnson & Johnson, with the trade name Xarelto. Rivaroxaban is a highly selective, oral drug that directly inhibits factor xa. By inhibiting factor xa, the endogenous and exogenous pathways of the coagulation cascade can be interrupted, and the generation of thrombin and thrombosis can be inhibited.
So how effective is rivaroxaban in treating venous thrombosis?
The main ingredient of Rivaroxaban tablets is Rivaroxaban, which is a red film-coated tablet that is clinically used in adult patients undergoing elective hip or knee replacement surgery to prevent venous thrombosis (VTE). The recommended dose of Rivaroxaban is 10 mg taken orally once daily. If the wound has stopped bleeding, the medication should be administered between 6-10 hours after surgery.
The four RECORD1-4 studies of Rivaroxaban to prevent VTE after total hip and knee replacement were a series of randomized, double-blind, multicenter clinical trials. The RECORD1-2 study evaluated the safety and effectiveness of rivaroxaban in preventing VTE in patients undergoing elective total hip arthroplasty.
The results showed that compared with enoxaparin, rivaroxaban could significantly reduce the incidence of total VTE, major VTE and symptomatic VTE, while the incidence of major bleeding events and other bleeding events was similar in the two groups. The RECORD3~4 study compared the safety and effectiveness of the above two drugs in preventing venous thromboembolism in patients after elective total knee replacement. The incidence of the primary endpoint event in the enoxaparin group was 18.9%, while that of rivaroxaban was only 9.6%. The difference between the two was statistically significant (P<0.001). The results showed that the efficacy of Rivaroxaban group was not inferior to that of traditional treatment, and the risk of bleeding was equivalent to or lower than that of traditional treatment.
The above is the treatment effect issue, I hope it can help everyone.
[ 免责声明 ] 本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。
.jpeg)